Study of the Follow-up of Stroke Treated With Anticoagulants "AOD"

Recruiting

Phase N/A Results N/A

Trial Description

Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap). Ischemic cardio-embolic stroke accounts for around 25% of ischemic strokes, and ischemic cardio-embolic stroke in a context of cardiac arrhythmia due to atrial fibrillation (CAAF) is the leading non-atheromatous cause. The aim of this study is to optimise the secondary prevention of CAAF-related stroke identified at the University Hospital of Dijon Burgundy in the framework of the recommendations of the '2010-2014 stroke plan' and the Compulsory Consultation at the 6th month (Directive DGOS//2015/262 of the 3rd August 2015)

Conditions

Interventions

  • Anticoagulants Drug
    ARM 1: Kind: Experimental
    Label: Stroke related to CAAF

Trial Population

patient with stroke resulting from occlusion of a cerebral artery (cerebral infarction) with a clot detached from the heart that exhibits an arrhythmia by Auricular Fibrillation or the occurrence of intracerebral hemorrhage

Outcomes

Type Measure Time Frame Safety Issue
Primary rate of stroke recurrences 12 months after inclusion

Sponsors